Impact of Statin Therapy on CD40:CD40L Signaling: Mechanistic Insights and Therapeutic Opportunities

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2024 Dec 16

PMID 39680334

Authors

Fatemeh Askarizadeh

Sercan Karav

Tannaz Jamialahmadi

Amirhossein Sahebkar

Affiliations

Soon will be listed here.

Abstract

Statins are widely utilized to reduce cholesterol levels, particularly in cardiovascular diseases. They interface with cholesterol synthesis by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase enzyme. Besides their primary effect, statins demonstrate anti-inflammatory and immune-modulating properties in various diseases, highlighting the pleiotropic effect of these drugs. The CD40:CD40L signaling pathway is considered a prominent inflammatory pathway in multiple diseases, including autoimmune, inflammatory, and cardiovascular diseases. The findings from clinical trials and in vitro and in vivo studies suggest the potential anti-inflammatory effect of statins in modulating the CD40 signaling pathway and downstream inflammatory mediator. Accordingly, as its classic ligand, statins can suppress immune responses in autoimmune diseases by inhibiting CD40 expression and blocking its interaction with CD40L. Additionally, statins affect intracellular signaling and inhibit inflammatory mediator secretion in chronic inflammatory diseases like asthma and autoimmune disorders such as myasthenia gravis, multiple sclerosis, systemic lupus erymanthus, and cardiovascular diseases like atherosclerosis. However, it is essential to note that the anti-inflammatory effect of statins may vary depending on the specific type of statin used. In this study, we aim to explore the potential anti-inflammatory effects of statins in treating inflammatory diseases by examining their role in regulating immune responses, particularly their impact on the CD40:CD40L signaling pathway, through a comprehensive review of existing literature.

References

Cheung B, Lauder I, Lau C, Kumana C . Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004; 57(5):640-51. PMC: 1884492. DOI: 10.1111/j.1365-2125.2003.02060.x. View

Kuipers H, Biesta P, Groothuis T, Neefjes J, Mommaas A, van den Elsen P . Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol. 2005; 66(6):653-65. DOI: 10.1016/j.humimm.2005.04.004. View

Takahashi H, Iwagaki H, Yagi T, Kanke T, Liu K, Yoshino T . Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction. Clin Immunol. 2007; 123(3):324-32. DOI: 10.1016/j.clim.2007.02.003. View

Yilmaz A, Reiss C, Weng A, Cicha I, Stumpf C, Steinkasserer A . Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006; 79(3):529-38. DOI: 10.1189/jlb.0205064. View

Serban C, Sahebkar A, Ursoniu S, Mikhailidis D, Rizzo M, Lip G . A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015; 5:9902. PMC: 4429557. DOI: 10.1038/srep09902. View

Chamani S, Kooshkaki O, Moossavi M, Rastegar M, Saffar Soflaei S, McCloskey A . The effects of statins on the function and differentiation of blood cells. Arch Med Sci. 2023; 19(5):1314-1326. PMC: 10507790. DOI: 10.5114/aoms/158546. View

Chamani S, Liberale L, Mobasheri L, Montecucco F, Al-Rasadi K, Jamialahmadi T . The role of statins in the differentiation and function of bone cells. Eur J Clin Invest. 2021; 51(7):e13534. DOI: 10.1111/eci.13534. View

Chrusciel P, Sahebkar A, Rembek-Wieliczko M, Serban M, Ursoniu S, Mikhailidis D . Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016; 253:194-208. DOI: 10.1016/j.atherosclerosis.2016.07.897. View

Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M . Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021; 12(2):237-251. PMC: 8061391. DOI: 10.1002/jcsm.12654. View

10.

Sahebkar A, Serban C, Ursoniu S, Mikhailidis D, Undas A, Lip G . The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2015; 115(3):520-32. DOI: 10.1160/TH15-08-0620. View

11.

Parizadeh S, Azarpazhooh M, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S . Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011; 46(4):333-40. DOI: 10.1007/s11745-010-3517-x. View

12.

Sahebkar A, Serban C, Mikhailidis D, Undas A, Lip G, Muntner P . Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015; 114(3):546-57. DOI: 10.1160/TH14-11-0937. View

13.

Mulhaupt F, Matter C, Kwak B, Pelli G, Veillard N, Burger F . Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res. 2003; 59(3):755-66. DOI: 10.1016/s0008-6363(03)00515-7. View

14.

Owens C . Statins and other agents for vascular inflammation. J Vasc Surg. 2012; 56(6):1799-806. DOI: 10.1016/j.jvs.2012.08.045. View

15.

Takemoto M, Liao J . Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21(11):1712-9. DOI: 10.1161/hq1101.098486. View

16.

Kwak B, Mulhaupt F, Myit S, Mach F . Statins as a newly recognized type of immunomodulator. Nat Med. 2000; 6(12):1399-402. DOI: 10.1038/82219. View

17.

Bahrami A, Parsamanesh N, Atkin S, Banach M, Sahebkar A . Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018; 135:230-238. DOI: 10.1016/j.phrs.2018.08.014. View

18.

Janic M, Lunder M, cerne D, Marc J, Jerin A, Skitek M . The "Rise-Peak-Fall" Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats. J Cardiovasc Pharmacol. 2016; 68(1):74-80. DOI: 10.1097/FJC.0000000000000393. View

19.

Schonbeck U, Libby P . Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation. 2004; 109(21 Suppl 1):II18-26. DOI: 10.1161/01.CIR.0000129505.34151.23. View

20.

Wang X, Zhou Y, Sun W, Li L . Rosuvastatin Attenuates CD40L-Induced Downregulation of Extracellular Matrix Production in Human Aortic Smooth Muscle Cells via TRAF6-JNK-NF-κB Pathway. PLoS One. 2016; 11(4):e0153919. PMC: 4847831. DOI: 10.1371/journal.pone.0153919. View